title: Oxidative stress and neurodegenerative diseases: a neurotrophic approach.
abstract: Neurotrophins are important neurotrophic factors involved in the survival, differentiation and function of a wide variety of neuron populations. A common feature for most neurotrophins is that they are synthesized as precursor proteins (pro-neurotrophins) that upon being processed by proteolysis render the mature active form responsible for most of their trophic functions. However, some of the pro-neurotrophin form of these proteins, such as the precursor form of NGF (pro-NGF), have been shown to induce opposite effects and trigger apoptosis on neurons through the p75NTR receptor. This suggests that the balance between the levels of proneurotrophin and neurotrophin must be tightly controlled. In this context, it has been shown that in conditions of oxidative stress due for instance to aging or the development of some neurodegenerative disease, neurotrophins are oxidatively modified at least by advanced glycation/lipoxidation end products (AGE/ALEs) which makes pro-NGF refractary to be processed. The lack of maturation and the imbalance in favor of the precursor form may change the pattern of active signaling pathways towards cell death, thus exacerbating the deleterious alterations, for instance during the development of neurodegenerative diseases. Besides that, AGE/ALEs also induce the processing of the pro-NGF receptor p75NTR by α- secretase which is followed by the processing by γ -secretase and the release of the intracellular domain of p75NTR (p75NTRICD). Once cleaved, p75NTRICD recruits two intracellular interactors, NRIF and TRAF6, which allows NRIF phosphorylation by JNK. The phosphorylated form of NRIF then translocates to the nucleus and induces the expression of pro-apoptotic proteins. In this chapter we will summarize the mechanisms by which ROS- induce protein modifications, which proteins are susceptible to be modified, how these modifications affect function and signaling and, finally, how they can be related to neurodegenerative diseases.
authors.forename: Carme
authors.initials: C
authors.lastname: Espinet
authors.forename: Hugo
authors.initials: H
authors.lastname: Gonzalo
authors.forename: Catherine
authors.initials: C
authors.lastname: Fleitas
authors.forename: Maria Jose
authors.initials: MJ
authors.lastname: Menal
authors.affiliation: Molecular and Developmental Neurobiology, Dept. Ciències Mèdiques Bàsiques, Facultat de Medicina, Universitat de Lleida/IRBLLEIDA, Rovira Roure 80, 25198, Lleida, Spain. carme.espinet@cmb.udl.cat.
authors.forename: Joaquim
authors.initials: J
authors.lastname: Egea
mesh_terms: D000818:Animals; D017127:Glycation End Products, Advanced / Q000378:metabolism; D006801:Humans; D009414:Nerve Growth Factors / Q000378:metabolism*; D019636:Neurodegenerative Diseases / Q000378:metabolism*; D018384:Oxidative Stress; D062106:Protein Degradation End Products / Q000378:metabolism; D017382:Reactive Oxygen Species / Q000378:metabolism; D017475:Receptors, Nerve Growth Factor / Q000378:metabolism*; D015398:Signal Transduction
chemical_list: D017127:Glycation End Products, Advanced; D009414:Nerve Growth Factors; D062106:Protein Degradation End Products; D017382:Reactive Oxygen Species; D017475:Receptors, Nerve Growth Factor